Paragon 28 (ZBH)

Executive Summary

Paragon 28 is a privately held medical device company founded in 2010, dedicated to addressing unmet needs in foot and ankle surgery. The company designs and manufactures innovative implants, instruments, and biologics tailored to surgeon preferences, with a focus on improving outcomes for complex foot and ankle conditions. With an estimated valuation of $17.6 billion and over 10 commercial products, Paragon 28 has established a strong presence in the orthopedic niche. The company operates on principles of creative innovation, high-quality cost-effective solutions, and evidence-based research. Paragon 28 continues to expand its portfolio and market reach, positioning itself as a leader in foot and ankle orthopedics. The company's commitment to research and collaboration with surgeons drives ongoing product development and clinical validation.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance or CE mark for next-generation ankle replacement system75% success
• Q3 2026Announcement of strategic partnership or distribution agreement with a major orthopedic company60% success
• Q4 2026Publication of positive 2-year clinical outcomes for a key product line80% success